The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

Diabetes Care

Volumn 19, Issue 11, 1996, Pages 1190-1193

  Chiasson, Jean Louis ^a,h   Josse, Robert G ^a,b   Leiter, Lawrence A ^c   Mime, Marko ^d   Nathan, David M ^a,e   Palmason, Carol ^b,f   Cohen, Art Robert M ^a,b   Wolever, Thomas M S ^g  

^a Research Center   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e HARVARD UNIVERSITY   (United States)

^f Bayer Inc   (Canada)

^g UNIVERSITY OF CINCINNATI   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029960361     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.11.1190     Document Type: Article

References (15)

1. Harris MI, Hadden \VC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36:523-534,1987
2. O'Sullivan JB, Mahan C: Prospective study of 352 young patients with chemical dia-betes. N Engl J Med 278:1038-1041, 1968
3. FitzGerald MG, Malins JM: Ten-year follow-up of repon on the Birmingham diabetes survey of 1961. Br MedJ 2:35-45, 1976
4. Saad MI; Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pima Indians. N Eng! J Med 319:1500-1506,1988
5. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDML: a balanced overview. Diabetes Care 15:318-368, 1992
6. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with noninsulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann intern Med 121:928-935,1994
7. Jenkins DJA, Taylor RH, Goff DY Fielden H, Misievicz JJ, Sarson DL, Bloom SR, Albert! KGMM: Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 30:951-954, 1981
8. Nagulesparan M, Savage PJ, Unger RH, Bennett PH: A simplified method to assess in vivo insulin resistance over a range of obesity Diabetes 28:980,1979
9. Clissold SP, Edwards C: Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and ther-apeutic potential. Drugs 35:214-243, 1988
10. Lecavalier L, Hamet P, Chiasson J-L: The effects of sucrose meal on insulin requirement in IDDM and its modulation by Acarbose. Diabete Metab 12:156-161, 1986
11. Reaven GM, Lardinois CK, Greenfield MS, Schwanz HC, Vreman HJ: Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl. 3):32-36, 1990
12. Schmack C, Prager RJF; Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk a-glucosidase inhibitor on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543,1989
13. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity Diabetes Care 13:610-630, 1990
14. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fûcker K: Therapeutic potentials of acarbose as firstline drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
15. Olefsky JM, Kolterman OG: Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. Amer J Med 70:151-168, 1981